[Ciprofloxacin in the treatment of staphylococcal endocarditis].
Ciprofloxacin was used in treatment of 5 patients with infectious endocarditis and bacterial vegetations on the values by the findings of the echocardiography. The hemocultures produced the growth of Staphylococcus epidermidis and S. aureus in 3 and 2 patients respectively. The degree of endocarditis was high in 3 patients and intermediate in 2 patients. The drug was administered intravenously in a dose of 200 mg 2 times a day for 4 weeks. The efficacy of the treatment was estimated by following-up the disease time course: the patients were examined prior to the treatment, every week during the treatment and after the treatment completion. The complex clinico-laboratory investigations showed that ciprofloxacin (Ciprinol, KRKA, Slavonia) is a highly efficient chemotherapeutic drug of the group of fluoroquinolones for the treatment of infectious (staphylococcal) endocarditis due to the sensitive microbes. The intravenous drug is useful in treatment of severe forms of infectious endocarditis. The drug is not toxic and well tolerated by the patients after its intravenous administration.
Demin
A A
AA
Drobysheva
V P
VP
D000328:Adult; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004697:Endocarditis, Bacterial / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy*
D002939:Ciprofloxacin
Tsiprofloksatsin v lechenii stafilokokkovogo éndokardita.